These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 16923923

  • 21. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers.
    Viganò A, Mora S, Giacomet V, Stucchi S, Manfredini V, Gabiano C, Salvini F, Cellini M, Tamburrini E, Puzzovio M, Zuccotti GV.
    Antivir Ther; 2011; 16(8):1259-66. PubMed ID: 22155907
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Review of tenofovir use in HIV-infected children.
    Aurpibul L, Puthanakit T.
    Pediatr Infect Dis J; 2015 Apr; 34(4):383-91. PubMed ID: 25247583
    [Abstract] [Full Text] [Related]

  • 25. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study.
    Lampertico P, Buti M, Fung S, Ahn SH, Chuang WL, Tak WY, Ramji A, Chen CY, Tam E, Bae H, Ma X, Flaherty JF, Gaggar A, Lau A, Liu Y, Wu G, Suri V, Tan SK, Subramanian GM, Trinh H, Yoon SK, Agarwal K, Lim YS, Chan HLY.
    Lancet Gastroenterol Hepatol; 2020 May; 5(5):441-453. PubMed ID: 32087795
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
    Boontanondha P, Nimitphong H, Musikarat S, Ragkho A, Kiertiburanakul S.
    Curr HIV Res; 2020 May; 18(1):52-62. PubMed ID: 31906840
    [Abstract] [Full Text] [Related]

  • 29. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group.
    Lancet; 2011 Jul 16; 378(9787):238-46. PubMed ID: 21763936
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team.
    Clin Infect Dis; 2018 Jan 06; 66(2):220-228. PubMed ID: 29020329
    [Abstract] [Full Text] [Related]

  • 32. A 10-year follow-up of bone mineral density in HIV-infected youths receiving tenofovir disoproxil fumarate.
    Giacomet V, Maruca K, Ambrosi A, Zuccotti GV, Mora S.
    Int J Antimicrob Agents; 2017 Sep 06; 50(3):365-370. PubMed ID: 28689877
    [Abstract] [Full Text] [Related]

  • 33. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, Lu B, McColl D, Chuck S, Enejosa J, Toole JJ, Cheng AK, Study 934 Group.
    N Engl J Med; 2006 Jan 19; 354(3):251-60. PubMed ID: 16421366
    [Abstract] [Full Text] [Related]

  • 34. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection.
    Fung HB, Stone EA, Piacenti FJ.
    Clin Ther; 2002 Oct 19; 24(10):1515-48. PubMed ID: 12462284
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.
    Viganò A, Bedogni G, Manfredini V, Giacomet V, Cerini C, di Nello F, Penagini F, Caprio C, Zuccotti GV.
    Clin Drug Investig; 2011 Oct 19; 31(6):407-15. PubMed ID: 21528939
    [Abstract] [Full Text] [Related]

  • 38. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B.
    Patterson SJ, George J, Strasser SI, Lee AU, Sievert W, Nicoll AJ, Desmond PV, Roberts SK, Locarnini S, Bowden S, Angus PW.
    Gut; 2011 Feb 19; 60(2):247-54. PubMed ID: 21036792
    [Abstract] [Full Text] [Related]

  • 39. Early changes in bone turnover and inflammatory biomarkers and clinically significant bone mineral density loss over 48 weeks among HIV-infected patients with virological failure of a standard first-line antiretroviral therapy regimen in the SECOND-LINE study.
    Mwasakifwa GE, Amin J, White CP, Center JR, Kelleher A, Boyd MA.
    HIV Med; 2020 Sep 19; 21(8):492-504. PubMed ID: 32573910
    [Abstract] [Full Text] [Related]

  • 40. Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health.
    McComsey GA, Lupo S, Parks D, Poggio MC, De Wet J, Kahl LP, Angelis K, Wynne B, Vandermeulen K, Gartland M, Cupo M, Aboud M, 202094 Sub-Study Investigators.
    AIDS; 2018 Feb 20; 32(4):477-485. PubMed ID: 29239893
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.